A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
1 - 18 Years, Male and Female
DFI17893 (primary)
NCI-2026-00162
2024-511508-18
U1111-1281-0103
Summary
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children
aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or
recurred after at least 2 prior lines of systemic therapy for cGVHD.
The purpose of Phase 1 is to determine the PK profiles and to establish the Recommended
Pediatric Equivalent Dose (RPED) of belumosudil in participants aged 1 to <12 years with
active moderate to severe cGVHD. Upon completion and evaluation of Phase 1, Phase 2 will
commence with the purpose of determining safety and efficacy (ORR by 24 weeks) of
belumosudil in participants aged 1 to <18 years.
Study details include:
The end of study is defined as 3 years after the last participant is recruited or all
participants have discontinued treatment, or have died, whichever comes first.
Minimum of 6 participants ages 1 to 6 years will be enrolled for each phase of study
Individual participant duration on study will consist of:
Up to 4 weeks for screening. Treatment until clinically significant progression of cGVHD,
relapse/recurrence of the underlying disease, start of a new systemic treatment for
cGVHD, experience of an unacceptable adverse event, request from participant or
Investigator, or until the end of the study is reached, whichever comes first.
30 days of post treatment safety follow-up. Long-term follow-up until death or end of
study, whichever occurs first.
Eligibility
- Participant must be 1 to <18 years of age, at the time the consent/assent is signed. For Phase 1: participant must be 1 to <12 years of age, at the time the consent/assent is signed. For Phase 2: participant must be 1 to <18 years of age, at the time the consent/assent is signed.
- Participant has undergone an allogeneic HCT
- Has active moderate to severe cGVHD, defined using the NIH Consensus diagnosis and staging criteria for which systemic therapy is required
- cGVHD is refractory to or has recurred after at least 2 prior lines of systemic treatment
- Has received at least two lines of prior systemic therapy for cGVHD, but no more than 5 lines.
- If participant receives corticosteroid therapy for cGVHD, the dose must be stable for at least 2 weeks prior to the first dose of the IMP
- Has a Lansky-Play (if aged <16 years) or Karnofsky (if aged =16 years) performance scale of =60
- Body weight of 8 kg and above
- Contraceptive use by sexually active male and female should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- The participant or their legally authorized representative (LAR) must be capable of giving signed informed consent
- Life expectancy of >6 months
- Participants can take the IMP orally or via a nasogastric tube
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.